Shaji K.
Kumar
Publicaciones en las que colabora con Shaji K. Kumar (27)
2024
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
2023
-
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Haematologica, Vol. 108, Núm. 11, pp. 2894-2912
2022
-
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)
Advances in Therapy
-
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Current Medical Research and Opinion, Vol. 38, Núm. 10, pp. 1759-1767
-
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood, Vol. 139, Núm. 6, pp. 835-844
-
Smoldering multiple myeloma current treatment algorithms
Blood cancer journal, Vol. 12, Núm. 9, pp. 129
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
-
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Advances in Therapy, Vol. 39, Núm. 5, pp. 1976-1992
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2019
-
Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)
Leukemia
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2018
-
Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond
Leukemia, Vol. 32, Núm. 2, pp. 252-262
2017
-
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582
-
Multiple myeloma
Nature Reviews Disease Primers, Vol. 3
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448